山东大学耳鼻喉眼学报 ›› 2012, Vol. 26 ›› Issue (1): 38-40.

• 论文 • 上一篇    下一篇

颌窦内控释制剂对慢性鼻窦炎转归的影响

陈志鹏1,王启荣1,崔朝阳1,陈海霞2   

  1. 1.山东大学附属千佛山医院耳鼻喉科, 济南 250014; 2.山东大学齐鲁医院药学部, 济南 250012
  • 收稿日期:2011-12-10 出版日期:2012-02-16 发布日期:2012-02-16
  • 通讯作者: 王启荣,主任医师,硕士生导师。 Email:wangqirong@sdhospital.com.cn
  • 作者简介:陈志鹏,硕士研究生。 Email:peng8327046@163.com
  • 基金资助:

    山东省卫生科技发展计划资助项目(2007·HW 118)

Influence of controlled-release formulations in maxillary sinus for chronic sinusitis

CHEN Zhi-peng1, WANG Qi-rong1, CUI Zhao-yang1, CHEN Hai-xia3   

  1.  Department of Otorhinolaryngology, Qianfo Mountain Hospital of Shandong University, Jinan 250014; 2. Department of Pharmaceutical, Qilu Hospital of Shandong University, Jinan 250012
  • Received:2011-12-10 Online:2012-02-16 Published:2012-02-16

摘要:

目的   研究红霉素控释制剂植入上颌窦内治疗慢性鼻窦炎的临床疗效。方法   在鼻内镜下经下鼻道开窗,将红霉素控释制剂植入上颌窦内。结果   48侧在21d人体环境下鼻腔分泌物中仍能检测到红霉素,45侧达到临床治愈标准。结论   红霉素控释制剂的临床应用可减少或终止口服或静脉用药,减少术后换药次数,减轻患者痛苦,临床疗效可靠。

关键词: 鼻窦炎;上颌窦;红霉素控释制剂;治疗效果

Abstract:

Objective   To study the implantation of controlled release formulations of erythromycin treatment of maxillary sinusitis in clinical efficacy. Methods    Controlledrelease formulations of erythromycin were implanted in the maxillary sinus by nasal antrostomy of inferior nasal meatus under endoscopy.  Result   48 sides were detected erythromycin from human nasal secretions after 21 days, and 45 sides reached standards of clinical cure. Conclusion   Clinical application of controlled-release formulations of erythromycin can reduce or stop oral or intravenous drug use, reduce the frequency of postoperative dressing, also reduces the suffering of patients.

Key words: Nasosinusitis; Maxillary sinus; Erythromycin sustained release preparation; Treatment outcome

中图分类号: 

  • R765.4+1
No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!